Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CFRX
Data at 60% enrollment.
Enrolling since 2019
37 trial sites
14 day follow up
A N Y D A Y N O W
Nader who is a convicted individual, being sued by three people for breach of fiduciary responsibility and insider enrichment author of religious books and worked at a Jewelry store before being a CEO that dumped the majority of his shares last year into the pump?
What a solid candidate.
Again, look at the backgrounds of the board and management team. Look at the percent ownership of institutional investors. Look at the banks that raised them money. Look at the conferences they present at. Look at the non-dilutive grant money they received. Look at how they focus on the trials and science and not update calls every month like they are running a time share program.
There is little doubt in my head that you are part of their PR campaign and are compensated to post.
We have an immigrant that went from anti-American to mainstream businessman leading a multi-billion dollar company that is about to bring amazing medical breakthroughs to the entire world....
....sorry...what company were you comparing CytoDyn to again ???
They don't have 20 PR/IR firms on the payroll. Some people actually believe in letting the science speak rather than BS. Look at our team and board. Who do you got?
Amazing.
And I'm suspecting all that capital infusion created such a ghost town here?
HAHAH you shook following me around. Too bad they already got CARB-X money twice. Too bad they got $50m from big name funds and too bad Pfizer invested in us 2X. Your CYDY dog shit only gets toxic money. CFRX insiders don't sell, your insiders dump as much as they can.
Helllllloooo.....I heard that_little_voice's also have something little... and that includes bank accounts...
BARDA's would touch this with your mother-in-law.....
Crazy this board is so quiet. Lets wake it up. BARDA decision any week and top line data late Q1 early Q2 2021.
Sleeping giant
Hey Trickledownfacists: Can you do a favor for me? This is only good news Friday info: but can you make it a point not to get banned again? I really value your input on this board and SEEL and, being so selfish, I look forward to your enthusiasm and posts.
I don't know how you got banned before, but please, just put that person on ignore, so you can't write a post
Okay?
See, all good news...
That's BS. Thanks for the find here.
Went big into SEEL. Still think his is a winner but a few months out before any trial news
I've been banned.
Fintels not great so don't buy it's info.When you coming back to stocktwits
Just saw it on fintel
Any proof besides Fintel?
Looks like federated sold all their shares.
Poor Poor TickleDown is Ticked
He missed the boat on CVM
Said it would be below $10 this week and he would add at $9.22
He seems Angry
Cheers
Read all about it here
https://seekingalpha.com/instablog/50299941-north-shore-research/5437459-cel-sci-idmcs-last-word-continue
No one cares. Cheers.
Out at $6.23
My work is done here!
Cheers!
Hello CFRX Team
Trickledown has been suspended here for violating their terms of service.
He was also suspended on StockTwits for violating their terms of service
His anger at me is unfounded. He is the one that broke the terms of service, not me.
Good luck, I will be exiting my short position by end of day.
I dont want to be caught on a short squeeze as I rarely ever short a stock
Cheers!
Short This Pig
The PUMP is over
I shorted at $6.75
Will close out my position at $5.50
Stop loss at $7.25
Address?
What you talking bout Willis?
You seem angry
Cheers!
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., F.A.C.P., President, Chief Executive Officer, and Chairman of ContraFect, will deliver the keynote address to open Maxim’s Infectious Disease Virtual Conference to be held on May 5, 2020. Dr. Pomerantz will discuss the urgent need for new antimicrobials and the medical attributes required to provide the basis for a renaissance in the anti-infectives sector. Dr. Pomerantz will also virtually present the Company’s portfolio and platform technology of DLAs during a panel discussion of “Non-antibiotic Anti-infectives.”
Keynote Presentation Details:
Keynote Presentation Title: The Rise of Antimicrobials
Time and Date: Tuesday, May 5, 2020, 10:00 a.m. ET
Panel Discussion Details:
Panel Session Title: Non-antibiotic Anti-infectives
Time and Date: Tuesday, May 5, 2020, 10:30 a.m. ET
Remember
Breakthrough designation approved.
The market HAS NOT valued that in yet.
Fast tracked.
Still enrolling.
Still adding sites.
Ceo says
$700M
-$1.5B in sales a year.
Easy
$5B
valuation.
If they enroll 10 patients a month at each site they will have 60% enrolled in 3.5 months. Been enrolling for 3 months now.
DATA READ OUT AFTER 60% ENROLLMENT!!!
Pfizer owns almost 10% and their VP is in the board of CFRX.
12.5M float with 10.5M shares held by insiders and funds.
Between PFE and Federated they own 30% of all shares!! Pfizer has the option to buy 10% more at a price over $12
Could be a HUGE week coming up. Could test $10 or higher
ANOTER TRIAL SITE ADDED
Beaten down. Huge news two weeks ago but lost in the covid panic.
Beaten down from $15
Any news or just beaten down?
Continuation next week.
Breakthrough designation approved.
The market HAS NOT valued that in yet.
Fast tracked.
Still enrolling.
Still adding sites.
Ceo says $700M-$1.5B in sales a year.
Easy $5B valuation.
If they enroll 10 patients a month at each site they will have 60% enrolled in 3.5 months. Been enrolling for 3 months now.
DATA READ OUT AFTER 60% ENROLLMENT!!!
Pfizer owns 10% and their VP is in the board of CFRX.
12.5M float with 10.5M shares held by insiders and funds.
Between $PFE and Federated they own 30% of all shares!! Pfizer has the option to buy 10% more at a price over $12.
That halt was the most ridiculous I've ever seen
So cheap,
Break through designation still not valued in.
The average market cap for large companies with BTD drugs is $138B
The average market cap for small cap companies who receive BTD is $8.3B
Cfrx market cap is $165M
FDA grants ‘breakthrough’ status to antibiotic alternative as ContraFect rushes to join fight against superbug
Amber Tong
Methicillin-resistant Staph aureus (Shutterstock)
An experimental drug that promises to be the first anti-infective agent to prove superior to vancomycin — an antibiotic approved in 1958 — has notched the FDA’s “breakthrough” status.
Roger Pomerantz
ContraFect said the designation was based on Phase II data in which exebacase was tested against a superbug known as methicillin-resistant Staph aureus, or MRSA. In a subgroup analysis, the clinical responder rate at day 14 was 42.8% higher than that among those treated with standard of care, the company said (p=0.010).
The 21% reduction in 30-day all-cause mortality, however, was not statistically significant with p=0.056.
Demonstrating superiority marks a first for the MRSA field, emphasized Roger Pomerantz, who jumped from Seres to become CEO for ContraFect last April. Allergan’s Dalvance, a structural relative to vancomycin, was approved based on non-inferiority.
ContraFect is now conducting a pivotal Phase III study to examine exebacase’s efficacy in all infections caused by Staph aureus, including right-sided endocarditis.
Cara Cassino
“Based on our interactions with the FDA regarding streamlined development of exebacase, this single Phase 3 study, in addition to the full package of data generated to date, may serve as the basis of a Biologics License Application for FDA review and potential approval of exebacase,” CMO Cara Cassino said in a statement.
MRSA, which comprises a group of Gram-positive bacteria, can cause infections in the skin, the heart, the respiratory system, bone and joint, and even the central nervous system.
Michael Messinger
Taking a page from bacteriophages — viruses that infect bacteria — ContraFect’s drug is a cell wall hydrolase enzyme, or lysin, that induces bacterial death by puncturing the cell wall. Its inventor, Vincent Fischetti of Rockefeller University, calls it an antibiotic alternative.
The company forecasts a $700 million market for the MRSA bacteremia indication provided that exebacase delivers in Phase III and gets the superiority label, CFO Michael Messinger told Endpoints News. They are also gunning for an expanded label covering all Staph aureus.
Author
FDA approves Execabase this morning!
Stock up.
Whole market taking a beating because of Covid-19.
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
580
|
Created
|
03/15/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |